AbbVie Reports Q3 Earnings Beat Driven by Skyrizi and Rinvoq Growth
AbbVie has reported third-quarter financial results that exceeded analyst expectations, characterized by a non-GAAP EPS of $3.82 and revenue of $17.4 billion. The company's performance was primarily driven by the continued double-digit year-over-year expansion of its key immunology products, Skyrizi and Rinvoq. The growth in these newer therapies has successfully offset the ongoing revenue decline resulting from patent expirations for Humira. Following these strong results, AbbVie has raised its full-year financial guidance, signaling confidence in its ability to navigate the transition toward its next generation of blockbuster drugs.
Tickers: $ABBV
Topics: earnings beat guidance raise pharmaceuticals product performance revenue growth